Expert: NIH Encourages Data from Clinical Trials be Disaggregated by Sex in Reporting

Sarah Temkin, MD, associate director for clinical research in the Office of Research on Women’s Health at the National Institutes of Health, discusses how clinical trials have evolved to address biological and sociological variables in patient health.

Pharmacy Times interviewed Sarah Temkin, MD, associate director for clinical research in the Office of Research on Women’s Health at the National Institutes of Health. Temkin was recently a keynote speaker at the Sex and Gender Health Education Summit, which looked to address the current progress to transform medical education and health care training.

During this discussion, Temkin addresses how clinical trials have evolved to address biological and sociological variables in patient health.

Related Content:

Women's HealthRetailHospital
New Analyses Strengthen Efficacy, Safety of Zuranolone for Depression
Study: Out-of-State Telemedicine Visits Were Common During the COVID-19 Pandemic
FDA Approves T-Cell Select Test for Automated Tuberculosis Testing